Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

44.21
+0.48001.10%
Pre-market: 44.19-0.0200-0.05%07:33 EDT
Volume:535.72K
Turnover:23.45M
Market Cap:2.57B
PE:-23.09
High:44.37
Open:43.82
Low:42.84
Close:43.73
52wk High:59.68
52wk Low:42.45
Shares:58.04M
Float Shares:51.67M
Volume Ratio:1.10
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.49
PE(LYR):-64.74

Loading ...

SUPN: Buy Rating Reiterated as Strong Growth Supports Unchanged $65 Price Target

TIPRANKS
·
May 06

Supernus Pharmaceuticals Earnings Call Signals Growth Momentum

TIPRANKS
·
May 06

Supernus reiterates full-year 2026 financial guidance

Reuters
·
May 06

Supernus Pharmaceuticals Q1 EPS $(0.04) Misses $(0.01) Estimate, Sales $207.705M Beat $192.918M Estimate

Benzinga Earnings
·
May 06

BRIEF-Supernus Pharmaceuticals Q1 Product Sales USD 150.8 Million

Reuters
·
May 06

Supernus Pharmaceuticals Q1 EPS USD -0.04

THOMSON REUTERS
·
May 06

Supernus Pharmaceuticals Outlook FY Revenue USD 840-870 Million

THOMSON REUTERS
·
May 06

Supernus Pharmaceuticals announces annual shareholder meeting

Reuters
·
May 01

Earning Preview: Supernus Pharmaceuticals this quarter’s revenue is expected to increase by 30.41%, and institutional views are bullish

Earnings Agent
·
Apr 28

TD Cowen Remains a Buy on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
Apr 23

Supernus to report first-quarter results, host conference call and webcast

Reuters
·
Apr 23

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

GlobeNewswire
·
Apr 23

Inventiva names Axel-Sven Malkomes CFO in leadership reshuffle

Reuters
·
Apr 23

Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)

TIPRANKS
·
Apr 13

A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong 1 Year Returns And Pipeline Progress

Simply Wall St.
·
Apr 09

Supernus enters into asset purchase agreement with Navitor

TIPRANKS
·
Apr 08

Supernus Pharmaceuticals Inc - Agreement Includes Five-Year Non-Compete and Non-Solicitation Covenant - SEC Filing

THOMSON REUTERS
·
Apr 08

Supernus Pharmaceuticals Inc - Enters Asset Purchase Agreement With Navitor on April 1, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 08

Supernus Pharmaceuticals Inc - to Buy Assets Related to Nv-5138 or Spn-820 Including Ip and Inventory - SEC Filing

THOMSON REUTERS
·
Apr 08

Supernus Pharmaceuticals Inc - Purchase Price Includes Phase 2B Study and Milestone Payments up to $350 Mln - SEC Filing

THOMSON REUTERS
·
Apr 08